CN105705141B - 缓释微球及其制备方法 - Google Patents

缓释微球及其制备方法 Download PDF

Info

Publication number
CN105705141B
CN105705141B CN201480016260.6A CN201480016260A CN105705141B CN 105705141 B CN105705141 B CN 105705141B CN 201480016260 A CN201480016260 A CN 201480016260A CN 105705141 B CN105705141 B CN 105705141B
Authority
CN
China
Prior art keywords
preparation
dispersed phase
betamethasone
sustained release
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480016260.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105705141A (zh
Inventor
T·里奇
B·C·萨努
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oakwood Laboratories LLC
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of CN105705141A publication Critical patent/CN105705141A/zh
Application granted granted Critical
Publication of CN105705141B publication Critical patent/CN105705141B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
CN201480016260.6A 2013-03-15 2014-03-14 缓释微球及其制备方法 Active CN105705141B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790554P 2013-03-15 2013-03-15
US61/790,554 2013-03-15
PCT/US2014/028657 WO2014144309A1 (en) 2013-03-15 2014-03-14 Sustained release microspheres and method of producing the same

Publications (2)

Publication Number Publication Date
CN105705141A CN105705141A (zh) 2016-06-22
CN105705141B true CN105705141B (zh) 2018-12-28

Family

ID=51537672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480016260.6A Active CN105705141B (zh) 2013-03-15 2014-03-14 缓释微球及其制备方法

Country Status (8)

Country Link
US (1) US9956177B2 (enExample)
EP (1) EP2968184B1 (enExample)
JP (2) JP2016515517A (enExample)
CN (1) CN105705141B (enExample)
CA (1) CA2909303C (enExample)
ES (1) ES2697696T3 (enExample)
MX (1) MX362187B (enExample)
WO (1) WO2014144309A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956177B2 (en) 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same
JP7576334B2 (ja) * 2019-03-29 2024-10-31 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
WO2022114876A1 (ko) * 2020-11-30 2022-06-02 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
EP4297753A4 (en) 2021-02-24 2025-01-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
US20240148662A1 (en) * 2021-03-11 2024-05-09 Oakwood Laboratories, Llc Methods and systems for making polymer microspheres
CN116999412A (zh) * 2023-08-03 2023-11-07 四川迈可隆生物科技有限公司 一种含有倍他米松药物的缓释微球制剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078673A1 (fr) * 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
CN102245201A (zh) * 2008-10-12 2011-11-16 麻省理工学院 免疫纳米疗法中的佐剂整合
WO2012019009A1 (en) * 2010-08-04 2012-02-09 Flexion Therapeutics Corticosteroids for the treatment of joint pain
WO2012112747A2 (en) * 2011-02-16 2012-08-23 Oakwood Laboratories, Llc Manufacture of microspheres using a hydrocyclone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
JP2002356419A (ja) * 2001-03-29 2002-12-13 Takeda Chem Ind Ltd 微粒薬物の製造法
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
GB2461186B (en) 2008-04-21 2010-09-01 Otonomy Inc Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
US9956177B2 (en) 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078673A1 (fr) * 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
CN102245201A (zh) * 2008-10-12 2011-11-16 麻省理工学院 免疫纳米疗法中的佐剂整合
WO2012019009A1 (en) * 2010-08-04 2012-02-09 Flexion Therapeutics Corticosteroids for the treatment of joint pain
WO2012112747A2 (en) * 2011-02-16 2012-08-23 Oakwood Laboratories, Llc Manufacture of microspheres using a hydrocyclone

Also Published As

Publication number Publication date
JP6808777B2 (ja) 2021-01-06
CN105705141A (zh) 2016-06-22
JP2016515517A (ja) 2016-05-30
MX362187B (es) 2019-01-08
ES2697696T3 (es) 2019-01-25
US20160030351A1 (en) 2016-02-04
CA2909303C (en) 2021-10-19
EP2968184A1 (en) 2016-01-20
MX2015012231A (es) 2016-05-05
EP2968184B1 (en) 2018-10-24
JP2019112471A (ja) 2019-07-11
WO2014144309A1 (en) 2014-09-18
BR112015022524A2 (pt) 2017-08-22
CA2909303A1 (en) 2014-09-18
EP2968184A4 (en) 2016-09-07
US9956177B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
CN105705141B (zh) 缓释微球及其制备方法
Matschke et al. Sustained-release injectables formed in situ and their potential use for veterinary products
DE69634277T2 (de) Kontrolliertes zuführsystem mit einer flüssigkeit von hoher viskosität
ES2637795T3 (es) Material de administración de fármacos hidrofóbico, método para la fabricación del mismo y métodos para la administración de una composición de administración de fármacos
US20230001396A1 (en) Compositions and methods for controlled delivery and protection of therapeutic agents
CN105744929B (zh) 由透明质酸制成的连续释放组合物及其治疗应用
AU2016228941B2 (en) Drug delivery composition comprising polymer-lipid hybrid microparticles
WO2018172494A1 (de) Extrudierte depotform zur anhaltenden wirkstofffreisetzung
CN110123779A (zh) 一种用于关节腔内注射的微球及其制备方法
CA3022399A1 (en) Biodegradable polymer microsphere compositions for parenteral administration
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
JP2016515517A5 (enExample)
US20230257653A1 (en) Fractal formulations
CN101522177A (zh) 包含表面改性微粒的微囊及其制备和使用方法
CN102083742A (zh) 制备均匀尺寸的、含难溶药物的聚合物纳米颗粒的方法
US20200254102A1 (en) Processing method for biopolymers using solvent combinations
JP2023538901A (ja) ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
Madan et al. Formulation and evaluation of microspheres containing ropinirole hydrochloride using biodegradable polymers
WO2017107908A1 (zh) 艾沙康唑的微粒给药组合物
EP4031108B1 (de) Extrudierte depotform mit kontrollierter wirkstofffreisetzung
JP2025522924A (ja) 薬物送達用バイオポリマー製剤
Che et al. In situ gel delivery system of methylprednisolone for post traumatic spinal injuries
JP7470954B2 (ja) ナノ粒子の製造方法
RU2552303C2 (ru) Способ получения фармацевтической композиции, содержащей алпразолам
CN102475888A (zh) 皮肤用含有辅料的药物微粒与含有辅料的水的透皮吸收药物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant